Note: based on a RGCC chemosensitivity analysis I have seen at a German clinic, Hydroxychloroquine has been effective in killing the cancer cells of 5 out 7 patients that were tested. It is one of very few available drugs that inhibits autophagy, a mechanism associated with its anticancer properties. Plaquenil side effects increased appetitie Mefloquine and chloroquine Hydroxychloroquine lupus pregnancy Hydroxychloroquine grade c pregnancy Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer Hydroxychloroquine is approved for the treatment of non-cancerous illnesses such as rheumatoid arthritis and systemic lupus erythematous. Researchers in the laboratory have tested tumors from patients with pancreatic cancer and have discovered that they have certain pathways inside the cells that promote growth and survival of the tumor. Fig. 4 Treatment of a pancreatic cancer patient with trametinib plus hydroxychloroquine T/HCQ led to a reduction in tumor marker cancer antigen 19-9 CA19-9 and overall tumor burden. Data. Hydroxychloroquine HCQ is an old FDA-approved drug used to treat malaria, and it inhibits autophagy. Based on this discovery and the drug’s availability, HCQ was tested in clinical trials for pancreatic cancer, but it did not have an impact when used alone. In cancer, authophagy is the process used by cancer cells to “self-eat” in order to survive. Specifically, if authophagy is prolonged this will become a lethal process to cancer. duing chemotheraphy, radiotheraphy, etc.) authophagy is used by cancer cells to survive. However, note that Chloroquine has other properties as well that may be very well related to anti cancer mechanism, such as zinc ionophore, and others (see below the section on mechanisms). Trametinib hydroxychloroquine pancreatic cancer KRAS Mutant Pancreatic Cancer No Lone Path to an., Protective autophagy elicited by RAF→MEK→ERK inhibition. Can hydroxychloroquine be taken with humiraHydroxychloroquine sulfate oral tablet 200 mgChloroquine pharmacology Apr 18, 2016 Pancreatic ductal adenocarcinoma PDAC is among the deadliest cancers with a dismal 7% 5-year survival rate and is projected to become the second leading cause of cancer-related deaths by 2020. KRAS is mutated in 95% of PDACs and is a well-validated. KRAS Mutant Pancreatic Cancer No Lone Path to an Effective.. Cancer Commons Cancer Commons and xCures Invite.. Phase I Study of Trametinib and Hydroxychloroquine in.. This phase I trial studies the sides effects and best dose of hydroxychloroquine when given together with trametinib in treating patients with pancreatic cancer that has spread to nearby tissue, lymph nodes, or other places in the body and cannot be removed by surgery. Trametinib is a cancer treatment that specifically targets the MEK1 and MEK2 proteins within the cancer cell. MEK1 and MEK2 are part of a pathway called MAPK, which is directed by KRAS. MEK1 and MEK2 are part of a pathway called MAPK, which is directed by KRAS. The Pancreatic Cancer Action Network PanCAN is dedicated to fighting the world’s toughest cancer. In our urgent mission to save lives, we attack pancreatic cancer on all fronts research, clinical initiatives, patient services and advocacy. Our effort is amplified by a nationwide network of grassroots support.